Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 236

Similar articles for PubMed (Select 22742532)

1.

Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy after intravitreal bevacizumab.

Cennamo G, Cesarano I, Vecchio EC, Reibaldi M, de Crecchio G.

J Ocul Pharmacol Ther. 2012 Dec;28(6):643-6. doi: 10.1089/jop.2011.0250. Epub 2012 Jun 28.

PMID:
22742532
2.

[Intravitreal bevacizumab treatment for choroidal neovascularization in Best's disease].

Perol J, Wolff B, Sahel JA, Le Mer Y.

J Fr Ophtalmol. 2011 May;34(5):281-6. doi: 10.1016/j.jfo.2010.11.021. Epub 2011 Apr 20. French.

3.

Ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy: one-year results.

Mimoun G, Caillaux V, Querques G, Rothschild PR, Puche N, Souied EH.

Retina. 2013 Mar;33(3):513-21. doi: 10.1097/IAE.0b013e3182753adb.

PMID:
23400081
4.

Intravitreal bevacizumab for choroidal neovascularization secondary to Best vitelliform macular dystrophy in a 6-year-old child.

Chhablani J, Jalali S.

Eur J Ophthalmol. 2012 Jul-Aug;22(4):677-9. doi: 10.5301/ejo.5000095.

PMID:
22139615
5.

Choroidal neovascularisation secondary to Best's disease in a 13-year-old boy treated by intravitreal bevacizumab.

Leu J, Schrage NF, Degenring RF.

Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1723-5. Epub 2007 Jun 29.

PMID:
17605026
6.

Long-term outcomes of intravitreal ranibizumab for choroidal neovascularization secondary to Best's disease: 3-year follow-up.

Ruiz-Moreno O, Calvo P, Ferrández B, Torrón C.

Acta Ophthalmol. 2012 Nov;90(7):e574-5. doi: 10.1111/j.1755-3768.2011.02363.x. Epub 2012 Feb 17. No abstract available.

PMID:
22339886
7.

Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma.

De Benedetto U, Battaglia Parodi M, Knutsson KA, Librando A, Bandello F, Lanzetta P, Iacono P.

J Ocul Pharmacol Ther. 2012 Oct;28(5):550-2. Epub 2012 May 3.

PMID:
22554238
8.

Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy.

Querques G, Querques L, Leveziel N, Bandello F, Souied EH.

J Fr Ophtalmol. 2013 Jan;36(1):e1-4. doi: 10.1016/j.jfo.2012.04.013. Epub 2012 Dec 4.

9.

[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].

Bidot ML, Malvitte L, Bidot S, Bron A, Creuzot-Garcher C.

J Fr Ophtalmol. 2011 Jun;34(6):376-81. doi: 10.1016/j.jfo.2011.03.004. Epub 2011 May 7. French.

10.

Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.

Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F.

Retina. 2011 Oct;31(9):1841-7. doi: 10.1097/IAE.0b013e31821800a4.

PMID:
21775926
11.

Treatment of choroidal neovascularization using intravitreal bevacizumab.

Pedersen R, Soliman W, Lund-Andersen H, Larsen M.

Acta Ophthalmol Scand. 2007 Aug;85(5):526-33. Epub 2007 May 18.

PMID:
17511757
12.

Intravitreal bevacizumab for choroidal neovascular membrane associated with Best's vitelliform dystrophy.

Rishi E, Rishi P, Mahajan S.

Indian J Ophthalmol. 2010 Mar-Apr;58(2):160-2. doi: 10.4103/0301-4738.60096.

13.

Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial.

Zhang H, Liu ZL, Sun P, Gu F.

Am J Ophthalmol. 2012 Feb;153(2):300-306.e1. doi: 10.1016/j.ajo.2011.07.019. Epub 2011 Oct 6.

PMID:
21982109
14.

Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.

Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, Bandello F.

Retina. 2013 Mar;33(3):593-7. doi: 10.1097/IAE.0b013e31826b6731.

PMID:
23190919
15.

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.

Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA; Pan-American Collaborative Retina Study Group.

Retina. 2008 Nov-Dec;28(10):1387-94. doi: 10.1097/IAE.0b013e3181884ff4.

PMID:
18827735
16.

Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.

Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N.

Retina. 2011 May;31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8.

PMID:
21358461
17.

[Intravitreal ranibizumab for choroidal neovascularisation associated with adult-onset vitelliform dystrophy].

Prieto-Calvo E, Torrón-Fernández Blanco C, Egea-Estopiñán C, Güerri-Monclús N, Ferrer-Novella E, Ruiz-Moreno O, Pablo-Julvez LE.

Arch Soc Esp Oftalmol. 2012 May;87(5):149-52. doi: 10.1016/j.oftal.2011.09.009. Epub 2012 Feb 9. Spanish.

PMID:
22554558
18.

Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results.

Scupola A, Tiberti AC, Sasso P, Savastano MC, Mastrocola A, Marangoni D, Minnella AM, Falsini B, Balestrazzi E.

Retina. 2010 May;30(5):739-47. doi: 10.1097/IAE.0b013e3181c59725.

PMID:
20038860
19.

Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.

Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.

Retina. 2007 Apr-May;27(4):432-8.

PMID:
17420694
20.

Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.

Furino C, Boscia F, Recchimurzo N, Besozzi G, Cardascia N, Sborgia L, Niro A, Sborgia C.

Acta Ophthalmol. 2009 Jun;87(4):404-7. doi: 10.1111/j.1755-3768.2008.01262.x. Epub 2008 Sep 8.

PMID:
18782335
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk